Ana Rosa Sáez Ibáñez, PhD Research Analyst, Clinical Accelerator and Venture Fund Ana Rosa Saez Ibanez, PhD, joined the Cancer Research Institute in 2022 as a Research Analyst at the CRI Clinical Accelerator and Venture Fund. In this role, she provides intelligence on immuno-oncology trends and the competitive landscape. She also assists in the team’s investment strategy, clinical trial design, drug development plans, and in establishing and maintaining effective relationships with industry, clinical and academic partners. Prior to joining CRI, Ana Rosa earned her Doctorate in Cancer Cell Biology at Uppsala University (Sweden) where she explored novel roles of receptor tyrosine kinases in promoting cancer cell migration. Following her degree, Ana Rosa joined Albert Einstein College of Medicine and Icahn School of Medicine at Mount Sinai (New York) as a postdoctoral fellow. There, she investigated the role of chaperone-mediated autophagy in mammary epithelial cell fate determination and development of metastatic breast cancer. She received her B.Sc. and M.Sc. in Biology and Biomedicine from the University of Valencia (Spain). Over the years, Ana Rosa has cultivated an interest in the different steps of the drug development process. In 2020, she was selected for the FDA-AACR oncology educational fellowship, a competitive regulatory affairs program led by the FDA OCE. In addition, she has also received training in biomedical entrepreneurship and has consulted for different investment banks as a biotech equity researcher. When not working, Ana Rosa enjoys catching up with friends, taking long walks around New York, and biking outside the city.